-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40

Benzinga·11/10/2026 15:35:07
Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target from $45 to $40.